Recs

1

Syneron Irons Out Some Wrinkles

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Syneron Medical (Nasdaq: ELOS  ) is hoping to smooth out the wrinkles in its growth with its latest offering. The aesthetic device maker's Matrix RF applicator, which is used to reduce facial wrinkles, was approved for use in the European Union Friday.

The Matrix RF applicator is an add-on that works with the company's eLight, eLaser, and eMax systems. Through radio frequencies -- that's what the RF stands for -- the device damages the layers under the skin, shrinks the collagen and promotes the generation of new collagen to smooth out the wrinkles. Unlike pure laser-based applications, the device doesn't damage the outer skin as much, leading to a quicker recovery.

Perhaps most importantly for Syneron, the Matrix RF has a disposable treatment tip. That'll supply a recurring revenue stream -- think Gillette razor blades -- something that the company has desperately needed. Syneron has also set up a "subscription" service for at least one of its fairly expensive machines, but the program isn't likely to bring in recurring revenue. It's more like an interest-free loan than a subscription because the price of the subscription can be used toward the purchase of the machine. I imagine most doctors will stay in the program just until they've paid enough to collect the machine.

The European approval for Matrix RF is probably more important than U.S. approval, given the growth Syneron has experienced overseas lately, though at least some of that was because of currency changes. In Europe, the market for its devices extends beyond doctors to other "aesthetic professionals," making for easier sales.

Syneron and other aesthetic device makers -- Palomar Medical (Nasdaq: PMTI  ) , Cutera (Nasdaq: CUTR  ) , and Cynosure (Nasdaq: CYNO  ) -- have been beaten down pretty well over the past year as discretionary spending has scaled back. The aesthetics market isn't likely to regain momentum until that turns around, but it looks like Syneron is setting itself up for success once it does.

More Foolishness on turnaround possibilities:

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Syneron is a recommendation of Motley Fool Rule Breakers, which is always on the hunt for medical device and other cutting-edge picks. See all of this newsletter service's latest discoveries with a free 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Syneron is also a Motley Fool Hidden Gems Pay Dirt selection. The Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 22, 2008, at 2:54 PM, marceloreddzinn wrote:

    Looking forward, also note that starting early next year, Syneron will be releasing its joint product with P&G which should provide some positive upside that is not reflected in the current price. Syneron has over $200M in Cash no Debt and continues to dominate the industry. The next year should be very good to Syneron given their current position and future prospects.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 733554, ~/Articles/ArticleHandler.aspx, 2/15/2012 12:11:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 12,878.28 4.24 0.03%
S&P 500 1,350.50 -1.27 -0.09%
NASD 2,931.83 0.44 0.02%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/14/2012 4:00 PM
ELOS $10.92 Up +0.13 +1.20%
Syneron Medical CAPS Rating: ****
PMTI $9.63 Up +0.09 +0.94%
Palomar Medical Te… CAPS Rating: ***
CYNO $16.44 Up +2.55 +18.36%
Cynosure, Inc. CAPS Rating: ****
CUTR $8.49 Up +0.67 +8.57%
Cutera, Inc. CAPS Rating: ***

Advertisement